Meeting
2018 ASCO Annual Meeting
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
Authors
Yarong Liu
HRAIN Biotechnology, Shanghai, China
Yarong Liu , Zhi Chen , Runhong Wei , Lin Shi , Feng He , Zixiao Shi , Tao Jin , Ronglin Xie , Baofeng Wei , Jing Chen , Hongliang Fang , Bo Zhu , Qi-Jing Li , Pin Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03093168
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8020)
DOI
10.1200/JCO.2018.36.15_suppl.8020
Abstract #
8020
Poster Bd #
29
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
First Author: Lu Han
Poster
2017 ASCO Annual Meeting
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
First Author: Jesus G. Berdeja
Poster
2023 ASCO Annual Meeting
Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
First Author: Mingyuan Sun
Poster
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
First Author: Ross Firestone